|
US4609675A
(en)
|
1984-08-17 |
1986-09-02 |
The Upjohn Company |
Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
|
|
IE62126B1
(en)
|
1986-03-12 |
1994-12-14 |
American Cyanamid Co |
Macrolide compounds
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
DE122009000079I2
(de)
|
1996-08-30 |
2011-06-16 |
Novo Nordisk As Novo Alle |
Glp-1 derivate
|
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1060191B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
DE69916811T2
(de)
|
1998-02-27 |
2005-04-14 |
Novo Nordisk A/S |
Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
|
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
AU3357800A
(en)
|
1999-02-05 |
2000-08-25 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
AU3240900A
(en)
|
1999-02-22 |
2000-09-04 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
|
DE60038097T2
(de)
|
1999-02-22 |
2009-02-12 |
Merrion Research I Ltd. |
Feste orale dosierungsform enthaltend einen resorptionsverstärker
|
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
|
AU2001275231A1
(en)
|
2000-06-02 |
2001-12-11 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
|
PL369268A1
(en)
|
2001-03-27 |
2005-04-18 |
Ranbaxy Laboratories Limited |
A stable pharmaceutical composition of pravastatin
|
|
HUP0304078A2
(hu)
|
2001-05-15 |
2004-04-28 |
Warner-Lambert Co. Llc |
Tömörítési eljárás nátrium-fenitoin gyógyszerkészítmény előállítására
|
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
CA2466863A1
(en)
|
2001-11-29 |
2003-06-05 |
Emisphere Technologies, Inc. |
Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
|
|
MXPA04007427A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Formulaciones de azitromicina granuladas por via seca.
|
|
AU2003208945B2
(en)
|
2002-02-20 |
2008-05-01 |
Emisphere Technologies, Inc |
Method for administering GLP-1 molecules
|
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
|
MXPA05012278A
(es)
|
2003-05-14 |
2006-02-10 |
Emisphere Tech Inc |
Composiciones para suministrar peptido yy y combatientes pyy.
|
|
MXPA06000446A
(es)
|
2003-07-11 |
2006-04-07 |
Novartis Ag |
Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
|
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
|
JP2007537141A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
新規なｇｌｐ−１化合物
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
|
JP4903690B2
(ja)
|
2004-05-06 |
2012-03-28 |
エミスフェアー・テクノロジーズ・インク |
Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
|
|
NZ550894A
(en)
|
2004-05-06 |
2011-02-25 |
Emisphere Tech Inc |
Solid dosage form of wetted heparin
|
|
ES2393324T3
(es)
|
2004-05-14 |
2012-12-20 |
Emisphere Technologies, Inc. |
Compuestos y composiciones para administrar principios activos
|
|
JP2006527064A
(ja)
|
2004-05-31 |
2006-11-30 |
サンア ファーマシューティカルス カンパニー リミテッド |
β−ラクタム系抗生物質を含む懸濁錠剤及びその製造方法
|
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
|
ES2542228T3
(es)
|
2004-07-08 |
2015-08-03 |
Novo Nordisk A/S |
Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
|
|
US20060078623A1
(en)
*
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性ｇｌｐ−１化合物
|
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー／エス |
遅延性のエキセンディン−４化合物
|
|
RU2382648C2
(ru)
|
2004-12-03 |
2010-02-27 |
Мерк Энд Ко., Инк. |
Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
|
|
JP5175553B2
(ja)
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
胃内滞留および制御放出型送達系
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
ES2484796T3
(es)
|
2005-03-18 |
2014-08-12 |
Novo Nordisk A/S |
Compuestos de GLP-1 extendidos
|
|
US20080260818A1
(en)
|
2005-03-28 |
2008-10-23 |
Dexcel Pharma Technologies Ltd. |
Controlled Absorption of Statins in the Intestine
|
|
US20070049557A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
|
AU2006318815B2
(en)
|
2005-11-17 |
2010-08-19 |
Novartis Ag |
Pharmaceutical composition
|
|
BRPI0710503A2
(pt)
|
2006-04-07 |
2011-08-16 |
Merrion Res Iii Ltd |
uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
|
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
WO2007146234A2
(en)
|
2006-06-09 |
2007-12-21 |
Merrion Research Ii Limited |
Solid oral dosage form containing an enhancer
|
|
WO2008003050A2
(en)
*
|
2006-06-28 |
2008-01-03 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
MX2009002121A
(es)
|
2006-09-07 |
2009-05-20 |
Hoffmann La Roche |
Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
|
|
AR062925A1
(es)
|
2006-09-22 |
2008-12-17 |
Novartis Ag |
Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
|
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
|
WO2008109385A2
(en)
|
2007-03-02 |
2008-09-12 |
Novartis Ag |
Oral administration of a calcitonin
|
|
CA2697504A1
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of California |
Salicylanilide modified peptides for use as oral therapeutics
|
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
US9241908B2
(en)
|
2007-10-16 |
2016-01-26 |
Biocon Limited |
Orally administrable solid pharmaceutical composition and a process thereof
|
|
US8022048B2
(en)
|
2007-11-02 |
2011-09-20 |
Emisphere Technologies, Inc. |
Method of treating vitamin B12 deficiency
|
|
US20090124639A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
CN102123697B
(zh)
|
2008-08-18 |
2015-06-10 |
安特拉贝欧有限公司 |
用于口服给予蛋白质的方法和组合物
|
|
WO2010092163A2
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications
|
|
EP2512454A2
(en)
|
2009-12-16 |
2012-10-24 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
|
WO2011116139A2
(en)
|
2010-03-16 |
2011-09-22 |
Chiasma Inc. |
Improved pharmaceutical compositions and methods of delivery
|
|
ES2900353T3
(es)
|
2010-04-07 |
2022-03-16 |
Vertex Pharma |
Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
|
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
KR102072202B1
(ko)
|
2012-03-22 |
2020-01-31 |
노보 노르디스크 에이/에스 |
Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
|
|
HUE064694T2
(hu)
|
2012-03-22 |
2024-04-28 |
Novo Nordisk As |
Továbbítószert tartalmazó készítmények és elõállításuk
|
|
WO2013189988A1
(en)
|
2012-06-20 |
2013-12-27 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
RS58039B1
(sr)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk As |
Oralno doziranje glp-1 jedinjenja
|